Related references
Note: Only part of the references are listed.Severe immune-related adverse events of immune checkpoint inhibitors for advanced non-small cell lung cancer: a network meta-analysis of randomized clinical trials
Jingjing Gu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)
Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy
Ying Jing et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
Lessons from Pharmacovigilance: Pulmonary Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy
Stephen W. Reese et al.
LUNG (2021)
Efficacy of left ventricular unloading strategies during venoarterial extracorporeal membrane oxygenation in patients with cardiogenic shock: a protocol for a systematic review and Bayesian network meta-analysis
Pengbin Zhang et al.
BMJ OPEN (2021)
Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer
Alvise Berti et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)
A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer
Yi-Dan Yan et al.
FRONTIERS IN IMMUNOLOGY (2021)
Risk of pneumonitis in cancer patients treated with PARP inhibitors: A meta-analysis of randomized controlled trials and a pharmacovigilance study of the FAERS database
Zhuo Ma et al.
GYNECOLOGIC ONCOLOGY (2021)
Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system
Chen Chen et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2021)
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
Hao Zhang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
Mechanisms Driving Immune-Related Adverse Events in Cancer Patients Treated with Immune Checkpoint Inhibitors
David J. Lee et al.
CURRENT CARDIOLOGY REPORTS (2021)
Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies
A. Freites-Martinez et al.
ACTAS DERMO-SIFILIOGRAFICAS (2021)
Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities
Yves Allenbach et al.
AUTOIMMUNITY REVIEWS (2020)
Renal adverse effects following the use of different immune checkpoint inhibitor regimens: A real-world pharmacoepidemiology study of post-marketing surveillance data
Gang Chen et al.
CANCER MEDICINE (2020)
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2020)
Management of Immune Checkpoint Inhibitor Toxicities
Quentin Durrechou et al.
Cancer Management and Research (2020)
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma
Sattva S. Neelapu et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase
Xuefeng Bai et al.
ENDOCRINE (2020)
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Caroline Robert et al.
LANCET ONCOLOGY (2019)
Myocarditis following the use of different immune checkpoint inhibitor regimens: A real-world analysis of post-marketing surveillance data
Qianqian Fan et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2019)
Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database
Kenichiro Sato et al.
JOURNAL OF NEURO-ONCOLOGY (2019)
Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors
Sophia C. Weinmann et al.
RHEUMATOLOGY (2019)
Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system
Yinghong Zhai et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Miguel F. Sanmamed et al.
CELL (2018)
Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis
Cheng Xu et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
Narek Shaverdian et al.
LANCET ONCOLOGY (2017)
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
I. Puzanov et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers
Benjamin L. Maughan et al.
FRONTIERS IN ONCOLOGY (2017)
Real-World Evidence - What Is It and What Can It Tell Us?
Rachel E. Sherman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
The reporting odds ratio and its advantages over the proportional reporting ratio
KJ Rothman et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2004)
Association of malignancy with diseases causing interstitial pulmonary changes
D Bouros et al.
CHEST (2002)
Share Paper
